Fig 1.
FoundationOne Liquid CDx assay utilization overview.
FoundationOne Liquid CDx was designed to allow comprehensive genomic profiling, understanding that shed of tumor DNA can be variable depending on a patient’s clinical characteristics.
Table 1.
Concordance between FoundationOne Liquid CDx and alpelisib CTAa for eligible PIK3CA alterationsb.
Table 2.
Progression-free survival among 165 CTA-positive/ FoundationOne Liquid CDx-positive patients.
Table 3.
Concordance between FoundationOne Liquid CDx and cobas EGFR Mutation Test v2 for EGFR exon 19 deletions and exon 21 L858R alterations.
Table 4.
Non-inferiority concordance study for clinical validity for the detection of EGFR exon 19 deletions and L858R substitutions in NSCLC (n = 177).
Table 5.
Point estimate and one-sided 95% upper confidence limit of ζPPA1, ζNPA1, ζPPA2, and ζNPA2.
Fig 2.
Box blots representing limits of detection (LoD) for variant categories in which 1069 tests were performed and 2180 variants were analyzed.
A. Short variant and rearrangement LoD, B. Copy number LoD, C. bTMB component LoD. MAF–Mutant Allele Fraction.
Table 6.
Limits of detection of a subset of clinically-actionable alterations in which 940 tests were performed and 46 unique variants were analyzed.
Table 7.
Reproducibility of platform-wide variant detection among 47 samples.
Table 8.
Concordance of FoundationOne Liquid CDx and an externally validated cfDNA NGS assay for platform-wide variants (n = 912 positive variants; n = 157,008 negative variants as determined by the comparator assay).
Table 9.
Concordance of FoundationOne Liquid CDx and an externally validated cfDNA NGS assay for select clinically actionable alterations (a subset of the results in Table 8).